Expanding the Scope of the Hatch-Waxman Act’s Patent Carve-Out Exception to the Identical Drug Labeling Requirement: Closing the Patent Litigation Loophole

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
(Visited 16 times, 1 visits today)